METHOD FOR TREATING RHEUMATOID ARTHRITIS Russian patent published in 2006 - IPC A61K33/06 A61P29/00 

FIELD: medicine, rheumatology.

SUBSTANCE: the innovation deals with basic immunomodeling and symptomatic antiphlogistic therapy and additionally - therapy with Calcium-D3 preparation at dosage correction, duration and multiplicity of therapy course being dependent upon phase, activity degree, the nature of disease flow and mineral density of bony tissue (MDBT). At highly progressing RA and during exacerbation phase one should apply Calcium-D3 for 14 d at low degree of activity, for 21 d at average degree and for 28 d in case of high degree of activity, moreover, at MDBT being below the standard one should apply Calcium-D3 at the dosage of 400 IU cholecalciferol (vitamin D3) and 1250 mg calcium carbonate in the evening and 200 IU cholecalciferol and 1250 mg calcium carbonate in the morning. At MDBT ranged within the norm it is necessary to apply Calcium-D3 at the dosage of 800 IU cholecalciferol and 2500 mg calcium carbonate both in the evening and in the morning. At slowly progressing RA for above 2 yr and at the phase of relative remission one should apply Calcium-D3 at the dosage of 200 IU cholecalciferol and 1250 mg calcium carbonate in the evening for prolonged period of time at 1-wk-long interval during 1-2 d. In case of early RA lasted for 2 yr at unknown character of its flow it is necessary to apply Calcium-D3 at the dosage of 400 IU cholecalciferol and 1250 mg calcium carbonate in the evening for 14 d. Therapy course should be carried out in 4-6 mo. The innovation provides optimal therapy for every combination of the phase, activity, the nature of RA flow and MDBT parameters that enables to decrease the chance for relapses and increase remission duration by 1.5-1.8 times.

EFFECT: higher efficiency of therapy.

3 cl, 2 ex